Keywords: Biphalin; Opioid receptors; MOR/DOR/KOR agonist; Synergistic analgesic effect; Cyclic peptides; Acm; acetamidomethyl; ACN; acetonitrile; BBB; blood brain barrier; Boc; t-butyloxycarbonyl; BOP; (benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluoro
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Salivary cortisol; Perceived stress; Randomized controlled trial; Moderation; Breast cancer; DMT;
Keywords: MS; multiple sclerosis; MS-RR; relapsing-remitting multiple sclerosis; MS-SP; secondary progressive multiple sclerosis; MS-PP; primary progressive multiple sclerosis; IFN-Ã; interferon-beta; GA; glatiramer acetate; DMT; disease-modifying treatment; CIS;
Keywords: AC927; 1-(2-phenylethyl)piperidine; AMPH; amphetamine; ATS; amphetamine-type stimulants; AZ66; 3-(4-(4-cyclohexylpiperazin-1-yl)pentyl)-6-flourobenzo(Abadias et al., 2013)thiazol-2(3H)-one; BD1008; N-(Brammer et al., 2006)-N-methyl-1-pyrrolidineethanamine
Keywords: Patient survey; Multiple sclerosis; MS; Pregnancy; Family planning; DMT; Teratogenicity; Disease modifying drugs;
Keywords: Demyelination; Multiple sclerosis; Pediatric; Incidental findings; ADEM; acute disseminated encephalomyelitis; CIS; clinically isolated syndrome; CNS; central nervous system; DIS; dissemination in space; DIT; dissemination in time; DMT; disease modifying
Keywords: Quality of life; Patient care management; Patient reported outcomes; EQ5D; Registries; Regression analysis; AIC; Aikake's Information Criterion; CIS; Clinically Isolated Syndrome; DMT; Disease-modifying Therapy; EDSS; Expanded Disability Status Scale; EQ-
Keywords: Peanut/maize intercropping; Transcriptional analysis; Iron nutrition; Fe; iron; SSH; suppression subtractive hybridization; ACC; aminocyclopropane-1-carboxylic acid synthase; MAs; mugineic acid family phytosiderophores; TOM1; transporter of mugineic acid
Keywords: AHR; aryl hydrocarbon receptor; BBB; blood-brain barrier; CNS; central nervous system; CIS; clinically isolated syndrome; EDSS; expanded disability status scale; EAE; experimental autoimmune encephalomyelitis; DC; dendritic cell; DMF; dimethyl fumarate; D
Keywords: CHI3L1; chitinase 3-like 1; MS; multiple sclerosis; RRMS; relapsing-remitting multiple sclerosis; CIS; clinically isolated syndrome; DMT; disease modifying therapies; IFNβ; interferon-beta; GA; glatiramer acetate; Chitinase 3-like 1; Interferon-beta; Gla
Keywords: DMT; disease modifying therapy; EDSS; expanded disability status scale; IFN; interferon; Multiple sclerosis; Disease modifying; Adherence;
Keywords: DBSI; diffusion basis spectrum imaging; DTI; diffusion tensor imaging; DMT; disease modifying therapy; ADC; apparent diffusion coefficient; PBH; persistent black hole; WM; white matter; GM; gray matter; Multiple sclerosis; Diffusion tensor imaging; Inflam
Keywords: AML; acute myeloid leukemia; CI; confidence interval; CPT; Current Procedural Terminology; DMT; disease-modifying therapy; ESA; erythropoiesis-stimulating agent; FDA; Food and Drug Administration; HCPCS; Healthcare Common Procedure Coding System; HMA; hyp
Keywords: MS; Multiple Sclerosis; PRIMS; Pregnancy In Multiple Sclerosis; EDSS; Expanded Disability Status Scale; DMT; disease modifying therapy; IVIg; intravenous immunoglobulin; GA; glatiramer acetate; INF; interferon; IM; intramuscular; EA; epidural analgesia; C
Keywords: DMT; disease modifying therapy; EDSS; Expanded Disability Status Scale; MRI; magnetic resonance imaging; MS; multiple sclerosis; Relapsing-remitting multiple sclerosis; Disease modifying therapy; Natalizumab; Fingolimod; Alemtuzumab; Systematic review;
Keywords: Metal activity; Agricultural soil; Land use; Parent material; DMT;
Keywords: New psychoactive substances; Synthetic cannabinoids; Synthetic cathinones; 2C-x; NBOMe; DMT; Motivations;
Keywords: CDMS; clinically definite MS; CIS; clinically isolated syndrome; CNS; central nervous system; DIS; dissemination in space; DIT; dissemination in time; DMT; disease-modifying therapies; NAA/Cr ratio; N-acetylaspartate/creatine ratio; NSWML; non-specific wh
Keywords: AdCSV; Adsorptive Cathodic Stripping Voltammetry; AFS; Atomic Fluorescence Spectroscopy; AGNES; Absence of Gradients and Nernstian Equilibrium Stripping; APDC; Ammonium 1-pyrrolidinedithiocarbamate; ASV; Anodic Stripping Voltammetry; BiFE; Bismuth Film El
Keywords: 2-AI; 2-aminoindane; 2C-B; 2,5-dimethoxy-4-bromophenethylamine; 5-IAI; 5-iodo-2-aminoindane; COMT; catechol-O-methyl transferase; CPP; conditioned place preference; DAT; dopamine transporter; DIO; diet-induced obese; DMT; N,N-dimethyltryptamine; EAAT2; ex
Keywords: AHSCT; autologous hematopoietic stem cell transplant; ARR; annualized relapse rate; BVL; brain volume loss; DMT; disease-modifying therapy; EDSS; Expanded Disability Status Scale; GA; glatiramer acetate; HRQoL; health-related quality of life; IFN; interfe
Keywords: AFBR; Anaerobic fluidized bed reactor; AFFFBR; Anaerobic fixed film fixed bed reactor; AOP; Advance oxidation processes; BA; Benzoic acid; CCR; Cross linked chitosen resin; CD; Current density; COD; Chemical oxygen demand; CPMAI; Chemical and petrochemica
Keywords: MS; multiple sclerosis; DMT; disease modifying therapy; RRMS; relapsing-remitting MS; NEDA; no evidence of disease activity; N/E; new or enlarging; GdE; gadolinium enhancing; KP; knowledge program; EQ-5D; European Quality of Life 5-Dimensions; PS; Perform
Keywords: Hallucinogens; Ayahuasca; DMT; Psilocybin; Mescaline; LSD; Neuroimaging; SPECT; PET; fMRI; Default mode network;
Keywords: AAN; American Academy of Neurology; ABN; Association of British Neurologists; AUD; Australian dollars; CIS; clinically isolated syndrome; CNS; central nervous system; DMT; disease-modifying therapy; EDSS; Kurtzke Expanded Disability Status Scale; EMA; Eur
Keywords: BID; twice-daily administration; BEYOND (trial); BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients; CARE MS I (trial); Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis; DMT; diseas
Keywords: DMT; decision-making task; EMT; emotional categorization and memory task; FERT; facial expression recognition task; GR; glucocorticoid receptor; HPA; hypothalamic-pituitary-adrenal; LEIDS-R; Leiden Index of Depression Sensitivity-Revised; MANOVA; mult
Keywords: LAI; leaf area index; FH; aboveground biomass at flowering; BM; aboveground biomass at maturity; DMT; dry matter translocation; DMTE; dry matter translocation efficiency; WUE; water use efficiency; ETc; crop evapotranspiration; GY; grain yield; Wheat; Dri
Keywords: SL; sphingolipid; S1P; sphingosine 1-phosphate; GCS; glucosylceramide synthase; GC; glucosylceramide; AC; ceramidase; SphK; sphingosine kinase; PPMP; D-threo-1-phenyl-2-hexadecanoylamino-3-morpholino-1-propanol; PDMP; D-threo-1-phenyl-2-decanoylamino-3-mo
Keywords: AFM; atomic force microscopy; API; active pharmaceutical ingredient; CA; contact angle; CAB; adhesive-cohesive balance; COPD; chronic obstructive pulmonary disease; DMT; Derjaguin-Muller-Toporov; DPI; dry powder inhaler; FPF; fine particle fraction;
Keywords: Choline monooxgenase; Betaine; Salt stress; Sugar beet; Transgenic plants; Sugar; BADH; betaine aldehyde dehydrogenase; Bet/ProT; betaine proline transporter; CMO; choline monooxygenase; DMT; dimethylglycine methyltransferase; GB; glycinebetaine; GSMT; gl
Keywords: QOL; Quality of life; DMT; Disease modifying therapy; UCSF; University of California, San Francisco; Ped QOL; Pediatric Quality of Life Inventory; TRAQ; Transition readiness assessment questionnaire; HCAQ; Healthcare skills assessment questionnaire; SES;
Keywords: 3OC6-HSL; 3-oxohexanoyl homoserine lactone; 3OC12-HSL; N-(3-oxododecanoyl)-l-homoserine lactone; ABC; the ATP (adenosine triphosphate)-binding cassette superfamily; ABI-PP; AcrAB/MexAB-specific inhibitor of pyridopyrimidine derivative; AHL; N-acylhomoseri
Keywords: BBB; blood-brain barrier; CNS; central nervous system; DMF; dimethyl fumarate; DMT; disease-modifying therapy; EDSS; Expanded Disability Status Scale; FDA; Food and Drug Administration; GA; glatiramer acetate; JCV; John Cunningham virus; MRI; magnetic res
Keywords: GFs; growth factors; ALG; alginate; HA; hyaluronic acid; HEP; heparin; PEI; polyethyleneimine; PHEMA; poly(2-hydroxyethyl methacrylate); PEG; poly(ethylene glycol); PEO; poly(ethylene oxide); DEX; dextran; PPO; poly(propylene oxide); PPG; poly(propylene g
Keywords: Vanadium stress; Oryza sativa; Transcriptome; ABA; abscisic acid; ABC; ATP binding cassette; CDPK; calcium-dependent protein kinase; DAB; 3,3â²-diamninobenzidine; DMT; drug/metabolite transporter; Grx; glutaredoxin; GST; glutathione S-transferase; HMs; h
Keywords: AR; androgen receptor; CYP; cytochrome P450; DBT; di-butyltin; DMT; dimethiltin; DPhT; diphenyltin; DHA; 5α-dihydroandrostenedione; DHT; 5α-dihydrotestosterone; DTT; dithiothreitol; EDC; endocrine-disrupting chemicals; EI; enzyme-inhibitor complex; ER;
Keywords: Ac; acetyl; acac; acetylacetonate; 9-BBN; 9-borabicyclo[3.3.1]nonane; Bn; benzyl; Boc; tert-butyloxycarbonyl; BOM; benzyloxymethyl; brsm; based on recovered starting material; Bz; benzoyl; CAN; ammonium cerium(IV) nitrate; Cbz; benzyloxycarbonyl; CD; circ
Keywords: Hallucinogens; LSD; DMT; Psilocybin; Mescaline; Tryptamines
Chemical space screening around Phe3 in opioid peptides: Modulating µ versus δ agonism by Suzuki-Miyaura cross-couplings
Keywords: BRET; bioluminescence resonance energy transfer; cAMP; cyclic adenosine monophosphate; Dmt; 2,6-dimethyltyrosine; DOP; δ-opioid receptor; EC50; half maximal effective concentration; EPAC; exchange protein directly activated by cAMP; GPI; guinea pig ileum
FDM and DMT performance comparison in high capacity point-to-point fibre links for intra/inter-datacentre connections
Keywords: Fibre optics communications; FDM; DMT; VCSEL;
Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week
Keywords: AE; adverse event; ARR; annualized relapse rate; CDW; confirmed disability worsening; CI; confidence interval; DMT; disease-modifying therapy; EDSS; Expanded Disability Status Scale; IFN; interferon; IM; intramuscular; IPD; individual patient data; NEDA;
Weekly enhanced T1-weighted MRI with Gadobutrol injections in MS patients: Is there a signal intensity increase in the dentate nucleus and the globus pallidus?
Keywords: DMT; disease modifying treatment; DN; dentate nucleus; GBCAs; gadolinium-based contrast agents; Gd; gadolinium; GP; globus pallidus; MCP; middle cerebellar peduncle; MS; multiple sclerosis; RR; relapsing remitting; SI; signal intensity; SOWM; semioval whi
Host behaviour of related compounds, TETROL and DMT, in the presence of two different classes of aromatic guest compounds
Keywords: Host-guest chemistry; Inclusion; DMT; TETROL; Toluene; Aniline;
Host compounds (+)-(2R,3R)-1,1,4,4-tetraphenylbutane-1,2,3,4-tetraol (TETROL) and (2R,3R)-(â)-2,3-dimethoxy-1,1,4,4-tetraphenylbutane-1,4-diol (DMT) with guests o-, m- and p- toluidine: A comparative investigation
Keywords: Host-guest chemistry; Supramolecular chemistry; Isomeric toluidines; TETROL; DMT;
DNA sequence-specific ligands. XVII. Synthesis, spectral properties, virological and biochemical studies of fluorescent dimeric bisbenzimidazoles DBA(n)
Keywords: topo-I; DNA topoisomerase I; DMT; DNA methyltransferase; HSV-1; herpes simplex virus type 1; CMV; cytomegalovirus; scDNA; supercoiled DNA; b.p.; base pairs; MABs; monoclonal antibodies; ACV; acyclovir; PBS; phosphate buffered saline; PFU/cells; plaque for
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting
Keywords: Disability worsening; Natalizumab; Relapsing-remitting multiple sclerosis; EDSS milestones; CP; cumulative probability; DMT; disease-modifying therapy; EDSS; Expanded Disability Status Scale; RRMS; relapsing-remitting multiple sclerosis; SPMS; secondary p
Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review
Keywords: Hallucinogen; LSD; Psilocybin; Anxiety; Life-threatening disease; Cancer; 5HT; 5-hydroxytryptamine (=Â serotonin); 5-HT2A; 5-hydroxytryptamine (serotonin) receptor 2A; ASC; altered states of consciousness; BDI; Beck Depression Inventory; DMT; N,N-dimethyl
Development of potent and proteolytically stable human neuromedin U receptor agonists
Keywords: Neuromedin U (NMU); NMU-8; Neuromedin U receptor agonists; Plasma stability; 1â²Nal; 1â²-naphtylalanine; 2â²Nal; 2â²-naphtylalanine; 7-OH-Tic; 7-hydroxy-L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; ACN; acetonitrile; AUC; area under the curve;
Homology modelling of human divalent metal transporter (DMT): Molecular docking and dynamic simulations for duodenal iron transport
Keywords: Duodenal iron transport; Human divalent metal ion transporter (DMT); Homology modelling; Molecular docking; Molecular dynamics simulations; DMT; Divalent Metal ion Transporter; FPN1; Ferroportin; hDMT1; Human Divalent Metal ion Transporter; IFD; Induced F